Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

July 27, 2023

Study Completion Date

July 27, 2023

Conditions
Atopic Dermatitis Eczema
Interventions
DRUG

EVO101

Topical Cream

Trial Locations (21)

23502

Pariser Dermatology Specialists, Norfolk

27262

Dermatology Consulting Services, PLLC, High Point

33134

Driven Research, LLC, Coral Gables

33172

Lenus Research and Medical Group, Miami

45040

Dermatologists of Southwest Ohio, Mason

46168

The Indiana Clinical Trials Center, Plainfield

46250

Dawes Fretzin Clinical Research Group, Indianapolis

55112

Minnesota Clinical Study Center, New Brighton

69144

SkinSpecialists, LLC, Omaha

72703

Clinical Trials Institute of Northwest Arkansas, Fayetteville

72758

Northwest AR Clinical Trials Center, PLLC, Rogers

77004

Center for Clinical Studies, Ltd LLC, Houston

77845

J&S Studies, Inc, College Station

78759

DermResearch, Austin

85008

Saguaro Dermatology, Phoenix

89148

JDR Dermatology Research, LLC, Las Vegas

90017

Metropolis Dermatology, Los Angeles

90045

Dermatology Research Associate, Los Angeles

90404

Clinical Science Institute, Santa Monica

92024

California Dermatology & Clinical Research Institute, Encinitas

97223

Oregon Medical Research Center, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Evommune, Inc.

INDUSTRY

NCT05579899 - Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis | Biotech Hunter | Biotech Hunter